BRCA2 and ovarian cancer: BRCA2 (TI), whose biallelic loss is associated to responsiveness to PARP inhibitors and diagnostic relevance with evidence level I, as well as prognostic implications, was altered in 2 out of 10 ovarian cancer patients.